Abstract
This paper briefly summarizes the results of a long-term, open pharmacotherapy trial in 16 patients with well-characterized mitochondrial disease. Outcome measures included repeated clinical evaluation, 31P-NMR spectroscopy and near-infrared spectroscopy. Treated patients appeared to survive longer with less functional disability and medical complications than typically seen in clinical practice.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Age of Onset
-
Antioxidants / therapeutic use*
-
Ascorbic Acid / therapeutic use
-
Child
-
Coenzymes
-
Female
-
Humans
-
Kearns-Sayre Syndrome / drug therapy*
-
Kearns-Sayre Syndrome / metabolism
-
MELAS Syndrome / drug therapy*
-
MELAS Syndrome / metabolism
-
MERRF Syndrome / drug therapy*
-
MERRF Syndrome / metabolism
-
Male
-
Methylprednisolone / therapeutic use*
-
Middle Aged
-
Mitochondrial Myopathies / drug therapy*
-
Mitochondrial Myopathies / metabolism
-
Oxidative Phosphorylation
-
Oxygen Consumption
-
Treatment Outcome
-
Ubiquinone / analogs & derivatives
-
Ubiquinone / therapeutic use
-
Vitamin E / therapeutic use
-
Vitamin K / therapeutic use
-
Vitamins / therapeutic use*
Substances
-
Antioxidants
-
Coenzymes
-
Vitamins
-
Vitamin K
-
Ubiquinone
-
Vitamin E
-
coenzyme Q10
-
Ascorbic Acid
-
Methylprednisolone